RYR3
Biomarker
RYR3 is involved in calcium signaling pathways. Its role as a biomarker is under investigation in oncology research contexts.
Approvals
1
Indications
1
Therapies
2
Mapped tests
1
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Indication-specific approvals
Approvals where RYR3 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Tumor-agnostic approvals
Approvals defined at the solid tumor level where RYR3 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report RYR3 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Test
Idylla CDx MSI Test
Biocartis US Inc.
Method
PCR
Specimen
Tissue (FFPE)
Reports RYR3 as part of its biomarker panel.
1 approvalView test profile →